Program
alixorexton
Also written as “ALKS 2680 Dose 1”, “ALKS 2680 Dose 2” and “ALKS 2680”.
Its studies are mostly in Narcolepsy · Idiopathic Hypersomnia · Sleep Wake Disorders · Sleepiness, led by Alkermes.
Furthest: phase 3, since Jan 6, 20257 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alkermes | 75 open or running | phase 3since Jan 6, 2025 | Apr 2, 2024 | Nov 2026phase 2 · NCT06843590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2024First study: phase 2 study in NarcolepsyFirst studyNCT06358950 · 92 enrolled · United States, Australia, Belgium and more
- Aug 13, 2024Phase 2 study in NarcolepsyNCT06555783 · 93 enrolled · United States, Australia, Belgium and more
- Jan 6, 2025Phase 3 study in Idiopathic HypersomniaNCT06767683 · 786 planned · United States, Australia, Belgium and more
- Feb 21, 2025Phase 2 study in Idiopathic HypersomniaNCT06843590 · 126 enrolled · United States, Australia, Belgium and more
- Mar 3, 20262 phase 3 studiesNCT07455383, NCT07502443
- Apr 15, 2026Phase 3 study in SleepinessNCT07540897 · 150 planned · United States, Belgium, Canada and more
- Oct 9, 2026Primary completion moved from 2028-06 to 2030-06Date moved laterphase 3 · +24 months · NCT06767683
Ahead
- Nov 2026Primary completion: phase 2 study in Idiopathic HypersomniaNCT06843590
- May 2027Primary completion: phase 3 study in Sleep Wake DisordersNCT07502443
- May 2027Primary completion: phase 3 study in NarcolepsyNCT07455383
- Jun 2027Primary completion: phase 3 study in SleepinessNCT07540897
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540897Sleepiness · United States, Belgium, Canada and more | 3 | Recruiting | Jun 2027 | 150 |
| NCT07502443Sleep Wake Disorders · United States, Australia, Belgium and more | 3 | Recruiting | May 2027 | 176 |
| NCT07455383Narcolepsy · United States, Australia, Belgium and more | 3 | Recruiting | May 2027 | 150 |
| NCT06843590Idiopathic Hypersomnia · United States, Australia, Belgium and more | 2 | Active, not recruiting | Nov 2026 | 126 |
| NCT06767683Idiopathic Hypersomnia · United States, Australia, Belgium and more | 3 | Recruiting | Jun 2030 | 786 |
| NCT06555783Narcolepsy · United States, Australia, Belgium and more | 2 | Completed | Nov 11, 2025 | 93 |
| NCT06358950Narcolepsy · United States, Australia, Belgium and more | 2 | Completed | Jun 19, 2025 | 92 |
How it is read
Names in the registry
- “ALKS 2680 Dose 1”, 3 entries
- “ALKS 2680 Dose 2”, 3 entries
- “ALKS 2680”, 3 entries
- “ALKS 2680, 4mg”, 1 entry
- “ALKS 2680, 6mg”, 1 entry
Conditions, from the studies’ own filings
- Narcolepsy, 3 studies
- Idiopathic Hypersomnia, 2 studies
- Sleep Wake Disorders, 1 study
- Sleepiness, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.